Kezar Life Sciences, Inc.
KZR
$4.50
$0.102.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 37.33% | 12.08% | 11.36% | 2.44% | -77.44% |
| Total Depreciation and Amortization | -7.50% | -6.47% | 4.82% | 0.39% | 198.94% |
| Total Amortization of Deferred Charges | 11.86% | 10.34% | 10.17% | 8.47% | 9.26% |
| Total Other Non-Cash Items | -47.78% | -59.78% | 47.43% | -24.67% | 86.15% |
| Change in Net Operating Assets | -92.00% | 123.21% | 374.87% | -125.57% | 14,287.93% |
| Cash from Operations | 11.35% | 13.42% | 21.15% | -9.60% | -19.50% |
| Capital Expenditure | -1,000.00% | 86.76% | -- | -- | 99.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.79% | 28.72% | -16.21% | 22.29% | 435.16% |
| Cash from Investing | -14.83% | 29.54% | -7.48% | 24.51% | 421.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -20.34% | -100.00% | -85.34% | -- | -88.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -20.34% | -100.00% | -85.34% | -- | -88.34% |
| Foreign Exchange rate Adjustments | -297.37% | 169.57% | 160.00% | 41.67% | -7.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.39% | 508.57% | 40.70% | 43.12% | 137.48% |